Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Dec;134(7):1437-46.
doi: 10.1038/sj.bjp.0704394.

Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells

Affiliations

Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells

P J Ferguson et al. Br J Pharmacol. 2001 Dec.

Abstract

1. Thymidylate synthase (TS) is a target for several anticancer drugs. We previously showed that an antisense oligodeoxynucleotide (ODN) directed against TS mRNA down-regulated TS protein and enhanced cytotoxicity of TS-targeting drugs [including 5-fluorodeoxyuridine (5-FUdR)] in HeLa cells. Patient tumours with increased TS expression are resistant to TS-targeting drugs. It was hypothesized that TS mRNA and consequently TS protein could be down-regulated in 5-FUdR-resistant cells that overexpress TS, sensitizing them to 5-FUdR cytotoxicity. In this study we assessed the capacity of an anti-TS antisense ODN to circumvent resistance dependent on TS overexpression. 2. Variant HeLa clones exhibiting 2 - 20 fold resistance to 5-FUdR were selected by exposing cultured cells to drug. Clones FUdR-5a, -25b, and -50a expressed TS protein levels 10 fold, 10 fold, and 17 fold higher (respectively) than parental cells. Cells were treated with antisense ODN 83 (a 2'-methoxy-ethoxylated, phosphorothioated 20-mer, complementary to a portion of the 3'-untranslated region of TS mRNA), or ODN 32 (a control ODN with the same base composition as ODN 83, but in randomized order). Twenty-four and 48 h following transfection (50-100 nM ODN, plus polycationic liposome), TS mRNA levels (by RT-PCR) and protein levels (by radiolabelled 5-FUdR-monophosphate binding) were decreased by at least 60% in ODN 83-treated cells compared with control ODN 32-treated cells. ODN 83 enhanced the cytotoxicity of 5-FUdR by up to 85% in both parental and 5-FUdR-resistant cell lines. 3. Antisense ODN can be used to down-regulate TS and attenuate drug resistance in TS-overexpressing cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Reduction of cellular levels of TS mRNA in HeLa cells and FUdR-resistant variants following treatment with antisense ODN 83. Following administration of ODNs to cultures, cells were harvested on days 1 and 2. Relative TS mRNA was visualized by RT – PCR, using GAPDH as a control for RNA integrity. This image is typical and representative of assays of cells harvested from three separate experiments.
Figure 2
Figure 2
Reduction in thymidylate synthase mRNA and protein levels by treatment of HeLa cells and FUdR-resistant variants with antisense ODN 83. Following a 4 h transfection of cells with ODN at the concentration indicated, one volume of medium was added, and cells were further incubated in ODN at 50% of the original concentration. Cells were harvested 1 and 2 days following initiation of exposure to ODN. (A) relative TS mRNA was assayed by RT – PCR, and compared with the level of the housekeeping gene product GAPDH. Data are summarized from the analysis of two separate determinations for day 1 and 3 for day 2, as represented by Figure 1. (B) TS protein level was measured by [3H]-FdUMP-binding. The TS content in the ODN 32-treated parental HeLa line was 0.983±0.132 pmol mg−1 (n=5) on Day 1, and 0.792±0.232 pmol mg−1 (n=5) on Day 2. All values presented are significantly different from the respective ODN 32-treated control (P<0.01).
Figure 3
Figure 3
Enhancement of FUdR cytotoxicity in HeLa cells and FUdR-resistant variants by treatment with antisense ODN 83. Cells were treated with ODNs for 4 h, followed by administration of FUdR without changing the medium. Cell number was determined after 4 days, and proliferation calculated as a percentage of that of control ODN-treated cells. (A) HeLa; (B) FUdR-5a; (C) FUdR-25b; (D) FUdR-50a. Error bars are smaller than the symbols.
Figure 4
Figure 4
Enhancement of FUdR cytotoxicity in HeLa cells and in FUdR-resistant variants by antisense ODN 83. Cells were treated with antisense ODN 83 or scrambled control ODN 32 for 4 h, followed immediately by coincubation with FUdR for 4 days. Proliferation was determined by increase in cell number. IC50 values were interpolated from plotted data, from a series of experiments represented by Figure 3. The value presented is the IC50 of the ODN 83-treated cells as a percentage of that of the control ODN 32-treated cells, calculated within individual experiments. All values for relative resistance are significantly different from that of control ODN-treated cells, P<0.001. aThis value is reproduced from Table 1 (see table for s.d. and n values for these averages). Resistance index was calculated by dividing the IC50 of the FUdR-resistant line by that of the parent HeLa cell line, within each individual experiment. bRelative proliferation is the relative increase in cell number, as a percentage of the control ODN-treated cells, of the cultures treated with antisense ODN 83 alone.

Similar articles

Cited by

References

    1. BENNETT C.F. Antisense oligonucleotides: is the glass half full or half empty. Biochem. Pharmacol. 1998;55:9–19. - PubMed
    1. BERG R.W., WERNER M., FERGUSON P.J., POSTENKA C., VINCENT M., KOROPATNICK D.J., BEHREND E. Tumor growth inhibition in vivo and G2/M cell cycle arrest induced by antisense oligodeoxynucleotide targeting thymidylate synthase. J. Pharmacol. Exp. Ther. 2001;298:477–484. - PubMed
    1. BERNE M.H.O., GUSTAVSSON B.G., ALMERSJO O., SPEARS P.C., FROSING R. Sequential methotrexate/5-FU: FdUMP formation and TS inhibition in a transplantable rodent colon adenocarcinoma. Cancer Chemother. Pharmacol. 1986;16:237–242. - PubMed
    1. BINDER R., HOROWITZ J.A., BASILION J.P., KOELLER D.M., KLAUSNER R.D., HARFORD J.B. Evidence that the pathway of transferrin receptor mRNA degradation involves an endonucleolytic cleavage within the 3′ UTR and does not involve poly(A) tail shortening. EMBO J. 1994;13:1969–1980. - PMC - PubMed
    1. BISHOP M.R., IVERSEN P.L., BAYEVER E., SHARP J.G., GREINER T.C., COPPLE B.L., RUDDON R., ZON G., SPINOLO J., ARNESON M., ARMITAGE J.O., KESSINGER A. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J. Clin. Oncol. 1996;14:1320–1326. - PubMed

Publication types

MeSH terms

LinkOut - more resources